Somatostatin Characteristics and Clinical Applications

Pharmacological Effects

• Somatostatin inhibits gastric motility, along with endocrine, exocrine, pancreatic, and pituitary secretions, and modifies memory formation in the CNS, according to the American Gastroenterological Association 1
• The synthetic analogue octreotide has a longer half-life of approximately 1.5-2 hours, which is beneficial for clinical use 2
• Somatostatin decreases splanchnic blood flow, which is utilized therapeutically in variceal bleeding management, as recommended by the European Association for the Study of the Liver 3

Clinical Utility

• Somatostatin controls hormone hypersecretion syndromes in neuroendocrine tumors, as suggested by the European Neuroendocrine Tumor Society 4, 2
• Somatostatin reduces fluid and electrolyte losses in high-output jejunostomy, according to the American Society for Parenteral and Enteral Nutrition 1
• Octreotide suppresses growth hormone secretion in acromegaly, as recommended by the Endocrine Society 2
• Long-acting formulations of somatostatin analogues, such as octreotide LAR and lanreotide, can be administered every 4 weeks, overcoming the short half-life limitation of native somatostatin, as approved by the European Medicines Agency 2

Somatostatin's Role in Gastrin Release Inhibition

Clinical Applications of Somatostatin

• The American Gastroenterological Association recommends somatostatin analogues, such as octreotide and lanreotide, to inhibit gastrin secretion in gastrinomas and other neuroendocrine tumors, with high affinity for sst2 receptors 5, 6, 7
• The effectiveness of somatostatin analogues in controlling gastric acid hypersecretion validates the physiological importance of the somatostatin-gastrin regulatory pathway, with a significant reduction in gastrin secretion 8